The funding is expected to enable Tesis to increase its production capability and clinical support and allow the company to move ahead with clinical initiatives for several of its proprietary products currently going through clinical validation.
This is Tesis’ first external financing since it started in early 2020. The new sum brings the company’s total to-date funding to $35 million.
